The average one-year price target for Genmab A (NasdaqGS:GMAB) has been revised to $55.27 / share. This is a decrease of ...

In its most recent quarterly report, Genmab A/S posted strong results, with third quarter sales reaching US$1.02 billion and net income more than doubling compared to a year earlier. The company also ...

An update from Genmab ( ($GMAB) ) is now available. On November 10, 2025, Genmab A/S announced a proposed private offering of $1.5 billion in ...

Medicxi has closed a €500M fund, expanded its leadership team and outlined its ongoing work in drug development and company ...

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, ...

Medicxi Announces €500 Million Fund VNew fund will continue Medicxi’s successful asset-centric company creation and investment strategy. LONDON, UK — November 14, 2025 — Medicxi, a leading European ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...

Detailed price information for Autolus Therapeutics Plc ADR (AUTL-Q) from The Globe and Mail including charting and trades.

UK-based life sciences venture capital firm Medicxi today announced the closing of Medicxi V, a 500 million-euros ($579.5 ...

Reimbursement authority NICE published draft guidance today giving a green light to the use of Columvi (glofitamab) in ...

Incyte has an analyst consensus of Moderate Buy, with a price target consensus of $93.86, a -13.30% downside from current levels. In a report released on November 7, Bank of America Securities also ...